In Tuesday’s Wall Street session, Hims & Hers Health Inc (NYSE:HIMS) shares traded at $58.50, down -3.26% from the previous session.
HIMS stock price is now 76.66% away from the 50-day moving average and 155.38% away from the 200-day moving average. The market capitalization of the company currently stands at $12.78B.
With the price target enhanced from $42 to $60, Morgan Stanley Downgraded its rating from Overweight to Equal-Weight for Hims & Hers Health Inc (NYSE: HIMS). On January 10, 2025, Citigroup Downgraded its previous ‘Neutral’ rating to ‘Sell’ on the stock increasing its target price from $24 to quote $25, while ‘BTIG Research’ rates the stock as ‘Buy’
In other news, Boughton Soleil, Officer bought 4,152 shares of the company’s stock on Feb 18 ’25. The stock was bought for $251,985 at an average price of $60.69. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 18 ’25, Officer Dudum Andrew bought 175,661 shares of the business’s stock. A total of $10,230,058 was incurred on buying the stock at an average price of $58.24. A total of 18.48% of the company’s stock is owned by insiders.
During the past 12 months, Hims & Hers Health Inc has had a low of $9.22 and a high of $64.84. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 2.14, and a quick ratio of 1.82.
The net profit margin was 8.15% and return on equity was 26.35% for HIMS. The company reported revenue of $401.56 million for the quarter, compared to $226.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 77.13 percent.
